The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”), is an international consortium dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.

Latest News
Epidemiology of Young Lung Cancer This study seeks to help researchers and clinicians better understand why an increasing number of young people are developing lung cancer. Specifically, we are looking to study the environmental and childhood exposures, and other risk factors for lung cancer in persons under age 40. READ MORE
SPACEWALK - A Study for Patients with ALK Drug Resistance This study seeks to help researchers and clinicians to better understand this kind of cancer and to develop new future lung cancer treatments. Specifically, we are looking for genetic changes in the ALK gene that could help to understand why a cancer has developed drug resistance. READ MORE
Genomics of Young Lung Cancer and INHERIT Studies Accepted for Presentation at ASCO Two Addario Lung Cancer Medical Institute research studies funded in part by the Bonnie J. Addario Lung Cancer Foundation chosen for presentation at the May/June 2015 American Society of Clinical [...] READ MORE
International Partnership to Address Lung Cancer Epidemic According to a recent study in the Annals of Oncology, lung cancer fatalities are set to overtake breast cancer deaths among European women for the first time this year. It [...] READ MORE
ALCMI Launches Genomics of Young Lung Cancer Study The Addario Lung Cancer Medical Institute (ALCMI) today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often [...] READ MORE
Exosome Diagnostics & ALCMI Announce Collaboration on Sequencing Blood CAMBRIDGE, Mass. and LOS ANGELES, Calif., Jan. 9, 2015 – Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced a strategic collaboration with the Addario Lung Cancer [...] READ MORE